Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,390.00GBp
19 Jul 2019
Change (% chg)

-12.00 (-0.19%)
Prev Close
6,402.00
Open
6,420.00
Day's High
6,454.00
Day's Low
6,359.00
Volume
1,610,776
Avg. Vol
2,052,336
52-wk High
6,634.00
52-wk Low
5,312.00

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals Says Has Cut Selected Early-Stage R&D Programs
Wednesday, 17 Jul 2019 

July 16 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS INC - HAS CUT SELECTED EARLY-STAGE RESEARCH AND DEVELOPMENT PROGRAMS.INOVIO PHARMACEUTICALS INC - DISCONTINUED FURTHER DEVELOPMENT OF ITS PHASE 1/2 STUDY IN ADVANCED BLADDER CANCER.INOVIO PHARMACEUTICALS INC - REDUCING ITS WORKFORCE BY 28%..INOVIO PHARMACEUTICALS - "SHARPENED ITS CORPORATE STRATEGY TO FOCUS ON COMMERCIAL DEVELOPMENT OF ITS LATE-STAGE HPV ASSETS".INOVIO PHARMACEUTICALS INC - REALIGNMENT ENABLES INOVIO TO FOCUS ON COMMERCIALIZING LEAD ASSET VGX-3100.INOVIO PHARMACEUTICALS INC - REALIGNMENT ENABLES INOVIO TO FOCUS ON RE-DEPLOYING RESOURCES TO RAPIDLY ADVANCE INO-3107.INOVIO PHARMA - REALIGNMENT HELPS CO TO FOCUS ON PARTNERSHIP WITH ASTRAZENECA TO ADVANCE MEDI0457 IN WITH CHECKPOINT INHIBITOR IN HPV-RELATED CANCERS.INOVIO PHARMACEUTICALS - CONTINUES TO EXPECT INTERIM PROGRESSION-FREE SURVIVAL & SAFETY DATA FOR GBM BEFORE YEAR-END 2019, OVERALL SURVIVAL DATA IN 2020.  Full Article

Astrazeneca's Imfinzi Granted U.S. Orphan Drug Designation For Small Cell Lung Cancer
Friday, 12 Jul 2019 

July 12 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR.ASTRAZENECA PLC - IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER.ASTRAZENECA PLC - IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER.  Full Article

Foundation Medicine Says Got FDA Approval For Foundationone CDX As Companion Diagnostic For Lynparza
Tuesday, 2 Jul 2019 

July 1 (Reuters) - Foundation Medicine::FOUNDATION MEDICINE - GOT FDA APPROVAL FOR FOUNDATIONONE CDX AS COMPANION DIAGNOSTIC FOR LYNPARZA FOR BRCA-MUTATED ADVANCED OVARIAN CANCER THERAPY.  Full Article

AstraZeneca Says Forxiga Receives Positive EU CHMP Opinion For DECLARE-TIMI 58 Cardiovascular Outcomes Data
Monday, 1 Jul 2019 

July 1 (Reuters) - AstraZeneca PLC ::FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR.FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR DECLARE-TIMI 58 CARDIOVASCULAR OUTCOMES DATA.CHMP RECOMMENDED CHANGE TO EUROPEAN MARKETING AUTHORISATION FOR FORXIGA IN PATIENTS WITH (T2D) TO INCLUDE CARDIOVASCULAR OUTCOMES DATA.REGULATORY REVIEWS AND SUBMISSIONS ARE ONGOING IN SEVERAL COUNTRIES, INCLUDING US, CHINA AND JAPAN.  Full Article

Astrazeneca Says Fasenra Receives Positive EU CHMP Opinion For Self-Administration And New Fasenra Pen
Monday, 1 Jul 2019 

July 1 (Reuters) - AstraZeneca PLC ::FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF.FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF-ADMINISTRATION AND NEW FASENRA PEN, A PRE-FILLED, SINGLE-USE AUTO-INJECTOR.CHMP OPINION CAN BE IMPLEMENTED WITHOUT NEED FOR A EUROPEAN COMMISSION DECISION DUE TO NATURE OF TYPE-II LABEL VARIATION.POSITIVE OPINION FOR SELF-ADMINISTRATION, FASENRA PEN IS SUPPORTED BY PHASE III GREGALE AND GRECO TRIALS, PHASE I AMES TRIAL.ANTICIPATES REGULATORY DECISION BY FDA ON SELF-ADMINISTRATION, NEW PRE-FILLED, SINGLE-USE AUTO-INJECTOR DEVICE IN SECOND HALF OF 2019.  Full Article

Astrazeneca Says Lynparza Approved In EU For 1st-Line Maintenance Treatment Of A Type Of Ovarian Cancer
Tuesday, 18 Jun 2019 

June 18 (Reuters) - AstraZeneca PLC ::LYNPARZA APPROVED IN EU FOR 1ST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER.EUROPEAN COMMISSION APPROVED LYNPARZA (OLAPARIB) AS A 1ST-LINE MAINTENANCE TREATMENT FOR WOMEN WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.  Full Article

Astrazeneca PLC Says Pooled Analyses Of The Roxadustat Global Phase III Programme Confirmed Cardiovascular Safety
Friday, 10 May 2019 

May 9 (Reuters) - AstraZeneca PLC ::SAYS ANNOUNCED TOP-LINE RESULTS FROM THE POOLED CARDIOVASCULAR (CV) SAFETY ANALYSES OF THE GLOBAL PHASE III PROGRAMME FOR ROXADUSTAT.POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III PROGRAMME CONFIRMED CARDIOVASCULAR SAFETY.ROXADUSTAT HAD BETTER OUTCOME VERSUS. EPOETIN ALFA IN INCIDENT-DIALYSIS PATIENTS AND COMPARABLE TO PLACEBO IN PATIENTS NOT ON DIALYSIS.  Full Article

Selumetinib Granted U.S. Breakthrough Therapy Designation In Neurofibromatosis Type 1
Monday, 1 Apr 2019 

April 1 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED U.S. BREAKTHROUGH THERAPY DESIGNATION IN NEUROFIBROMATOSIS TYPE 1.MERCK & CO INC - DESIGNATION BASED ON PHASE 2 SPRINT TRIAL IN PEDIATRIC PATIENTS WITH NF1 PLEXIFORM NEUROFIBROMAS.MERCK & CO INC - SELUMETINIB IS A MEK 1/2 INHIBITOR BEING CO-DEVELOPED BY ASTRAZENECA AND MERCK.  Full Article

Astrazeneca Says Selumetinib Gets Breakthrough Therapy Designation
Monday, 1 Apr 2019 

April 1 (Reuters) - AstraZeneca PLC ::SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION.BREAKTHROUGH THERAPY DESIGNATION BASED ON PHASE II SPRINT TRIAL IN PAEDIATRIC PATIENTS WITH NF1 PLEXIFORM NEUROFIBROMAS.SELUMETINIB IS A MEK 1/2 INHIBITOR BEING CO-DEVELOPED BY ASTRAZENECA AND MERCK & CO .  Full Article

AstraZeneca Completes Placing Raising About 2.69 Bln Pounds
Friday, 29 Mar 2019 

March 29 (Reuters) - AstraZeneca PLC ::ANNOUNCE SUCCESSFUL COMPLETION OF PLACING ANNOUNCED EARLIER TODAY.TOTAL OF 44,386,214 NEW ORDINARY SHARES OF TWENTY-FIVE CENTS EACH IN COMPANY HAVE BEEN PLACED.PLACING SHARES BEING ISSUED REPRESENT APPROXIMATELY 3.5 PER CENT. OF ISSUED ORDINARY SHARE CAPITAL OF COMPANY.PLACING RAISED PROCEEDS OF APPROXIMATELY £2.69 BILLION ($3.5 BILLION AT A GBP:USD AVERAGE EXCHANGE RATE OF 1.3034) (BEFORE EXPENSES).  Full Article

Photo

AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes

British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare-type of the condition.